Cancer Communications
Overview
Cancer Communications is a peer-reviewed journal dedicated to advancing cancer research and communication. It publishes high-quality articles covering various aspects of cancer biology, diagnosis, treatment, and prevention. With a focus on promoting interdisciplinary collaboration, the journal serves as a platform for scientists, clinicians, and researchers to share their findings and insights, ultimately contributing to the global fight against cancer.
Details
Details
Abbr.
Cancer Commun (Lond)
Publisher
Wiley
Start
2018
End
Continuing
e-ISSN
2523-3548
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 4440
79
SJR / Ranks: 266
4950
CiteScore / Ranks: 356
19.90
JIF / Ranks: 201
16.2
Recent Articles
11.
Shan D, Song J, Ren Y, Zhang Y, Ba Y, Luo P, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 39945125
Copper, one of the essential nutrients for the human body, acts as an electron relay in multiple pathways due to its redox properties. Both deficiencies and excesses of copper lead...
12.
Bolek H, Kuzu O, Camoz E, Sim S, Sekmek S, Karakas H, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 39927571
No abstract available.
13.
Gomari M, Ghantabpour T, Pourgholam N, Rostami N, Hatfield S, Namazifar F, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 39901621
Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging...
14.
Sripan P, Proute M, Ngo-Giang-Huong N, Rangdaeng S, Putiyanun C, Halue G, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39878323
No abstract available.
15.
Lu K, Wijaya C, Yao Q, Jin H, Feng L
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39865459
Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances...
16.
Circulating tumor cells share RNA modules with early embryo trophectoderm and with metastatic cancer
Volinia S, Terrazzan A, Kaminski T, Jadzewski K, Reali E, Bianchi N, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39853715
No abstract available.
17.
Jin J, Fuchslocher F, Carreno-Gonzalez M, Zahnow F, Ceranski A, Will R, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39834137
No abstract available.
18.
Baek H, Han G, Cho E, Xu J, Ki M, Park E, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39826130
No abstract available.
19.
Ma J, Wang J, Xu T, Ouyang Q, Wang X, Wang J, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39825877
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness...
20.
Malmberg R, Agema B, Hofman M, Oosterveld S, Bins S, Dumoulin D, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39817458
No abstract available.